YeeMeng
2021-09-21
Great news for Pfizer?
J&J Says Covid-19 Vaccine Booster Two Months After First Shot Increases Protection<blockquote>强生公司表示，第一针注射两个月后的Covid-19疫苗加强剂可增强保护作用</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":869008484,"tweetId":"869008484","gmtCreate":1632223362448,"gmtModify":1632801982442,"author":{"id":3582597737343890,"idStr":"3582597737343890","authorId":3582597737343890,"authorIdStr":"3582597737343890","name":"YeeMeng","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":12,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Great news for Pfizer?</p></body></html>","htmlText":"<html><head></head><body><p>Great news for Pfizer?</p></body></html>","text":"Great news for Pfizer?","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/869008484","repostId":1157787805,"repostType":4,"repost":{"id":"1157787805","kind":"news","pubTimestamp":1632222985,"share":"https://www.laohu8.com/m/news/1157787805?lang=zh_CN&edition=full","pubTime":"2021-09-21 19:16","market":"us","language":"en","title":"J&J Says Covid-19 Vaccine Booster Two Months After First Shot Increases Protection<blockquote>强生公司表示，第一针注射两个月后的Covid-19疫苗加强剂可增强保护作用</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1157787805","media":"The Wall Street Journal","summary":"Trial participants in the U.S. who received a second dose eight weeks after the first had 94% protec","content":"<p> <b>Trial participants in the U.S. who received a second dose eight weeks after the first had 94% protection against the illness.</b> Johnson & JohnsonJNJ-0.57%said a booster dose of its Covid-19 vaccine administered two months after the first shot increased protection against symptomatic illness in trial participants, as federal regulators evaluate data for the country’s strategy for rolling out boosters.</p><p><blockquote><b>美国的试验参与者在第一剂疫苗八周后接受第二剂疫苗，对该疾病的保护率为94%。</b>强生公司(Johnson&JohnsonJNJ-0.57%)表示，在联邦监管机构评估该国推出加强疫苗战略的数据时，在第一针注射两个月后注射了加强剂量的Covid-19疫苗，增强了对试验参与者症状性疾病的保护。</blockquote></p><p> Data released Tuesday from a late-stage clinical trial showed that study participants in 10 countries including the U.S. who received a second dose of the company’s vaccine two months after the first had 75% protection against symptomatic Covid-19. Participants in the U.S. had 94% protection against the illness. J&J didn’t explain the reason for the difference in efficacy rates.</p><p><blockquote>周二发布的一项后期临床试验数据显示，包括美国在内的10个国家的研究参与者在第一剂疫苗两个月后接种了第二剂该公司的疫苗，对有症状的Covid-19有75%的保护作用。美国的参与者对这种疾病有94%的保护。强生没有解释有效率差异的原因。</blockquote></p><p> A double dose of the vaccine provided participants with 100% protection against severe or critical Covid-19 at least two weeks after the second shot, J&J said.</p><p><blockquote>强生表示，在第二次注射后至少两周内，双倍剂量的疫苗为参与者提供了100%的针对严重或危重Covid-19的保护。</blockquote></p><p> The company earlier this year said a large clinical trial showed thata single dose of its vaccine was 66% effectiveat protecting people from moderate to severe Covid-19.</p><p><blockquote>该公司今年早些时候表示，一项大型临床试验表明，其单剂疫苗在保护人们免受中度至重度Covid-19感染方面的有效性为66%。</blockquote></p><p> “We now have generated evidence that a booster shot further increases protection against Covid-19 and is expected to extend the duration of protection significantly,” said Paul Stoffels, chief scientific officer at J&J. The company said it has shared available data with the Food and Drug Administration.</p><p><blockquote>强生首席科学官保罗·斯托菲尔斯(Paul Stoffels)表示：“我们现在有证据表明，加强注射进一步增强了对Covid-19的保护，预计将显着延长保护持续时间。”该公司表示，已与食品和药物管理局分享了可用数据。</blockquote></p><p> The late-stage study tested a two-dose regimen of the vaccine in about 32,000 people aged 18 and over in the U.S., Belgium, Brazil, Colombia, France, Germany, the Philippines, South Africa, Spain and the U.K., J&J said. The company said about half of participants received the placebo but didn’t say how many participants were in the U.S.</p><p><blockquote>J&J说，这项后期研究在美国、比利时、巴西、哥伦比亚、法国、德国、菲律宾、南非、西班牙和英国的约32,000名18岁及以上的人中测试了两剂疫苗。该公司表示，大约一半的参与者接受了安慰剂，但没有透露有多少参与者在美国。</blockquote></p><p> J&J said Tuesday that an extra shot given two months after the firstboosted antibody levels four to six times higherthan observed after the single shot. It said a booster administered six months after the first shot initially increased antibody levels ninefold and continued to climb to 12-fold higher four weeks after the second shot. J&J released some of thesix-month boosting datain August.</p><p><blockquote>强生周二表示，第一次加强抗体水平两个月后额外注射的抗体水平比单次注射后观察到的高出四到六倍。报告称，第一次注射后六个月注射的加强剂最初使抗体水平增加了九倍，并在第二次注射后四周继续攀升至12倍。J&J在8月份发布了一些六个月的提振数据。</blockquote></p><p> Neither that data nor the results released Tuesday have been peer reviewed or published in a scientific journal.</p><p><blockquote>这些数据和周二发布的结果都没有经过同行评审或发表在科学期刊上。</blockquote></p><p> “The data are supportive of giving a second shot of the J&J vaccine, anywhere from two months onwards,” said Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop J&J’s vaccine. “The longer you wait, the better the boost will likely be.”</p><p><blockquote>帮助开发强生疫苗的波士顿贝斯以色列女执事医疗中心免疫学家丹·巴鲁奇(Dan Barouch)表示：“数据支持在两个月后注射第二针强生疫苗。”“等待的时间越长，提振效果可能就越好。”</blockquote></p><p> He said some countries might choose to offer boosters, while others might stick with a single shot. “Different people or different countries might actually make different choices based on what their desires or needs are,” Dr. Barouch said.</p><p><blockquote>他说，一些国家可能会选择提供加强剂，而另一些国家可能会坚持注射一针。“不同的人或不同的国家实际上可能会根据他们的愿望或需求做出不同的选择，”巴鲁奇博士说。</blockquote></p><p> J&J also highlighted data it said showed its single-shot vaccine offered durable protectioneven as the Delta variant spreads.</p><p><blockquote>强生公司还强调了数据，称其单针疫苗即使在德尔塔变异毒株病毒传播的情况下也能提供持久的保护。</blockquote></p><p> In a study of about 390,000 people in the U.S. who received the J&J vaccine compared with 1.52 million similar unvaccinated people from March to late July 2021,the single-dose vaccine was 79% effectiveagainst infections and 81% effective against hospitalizations related to Covid-19.</p><p><blockquote>在一项对2021年3月至7月下旬美国约390,000名接种强生疫苗的人与152万名类似未接种疫苗的人进行的研究中，单剂疫苗对感染的有效率为79%，对与Covid-19相关的住院有效率为81%。</blockquote></p><p> The Biden administration is hoping to begin at least part of its boosting strategy this week. It is waiting for the FDA to authorize additional doses of the vaccine fromPfizerInc.andBioNTech SEfor people who are 65 years old and over or at high risk of developing severe Covid-19. A Centers for Disease Control and Prevention advisory panel is set to discuss the Pfizer boosting strategy on Wednesday and Thursday.</p><p><blockquote>拜登政府希望本周至少开始部分提振战略。它正在等待FDA批准辉瑞公司和BioNTech为65岁及以上或患有严重Covid-19高风险的人群提供额外剂量的疫苗。疾病控制和预防中心顾问小组将于周三和周四讨论辉瑞的加强策略。</blockquote></p><p> Plans to offer boosters more widely were scaled back as federal health officials and medical expertsremain divided over the need for boostersand regulators have asked for more time to review data from J&J andModernaInc.</p><p><blockquote>由于联邦卫生官员和医学专家在加强剂的需求上仍存在分歧，监管机构要求更多时间来审查强生和现代公司的数据，更广泛地提供加强剂的计划被缩减。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Says Covid-19 Vaccine Booster Two Months After First Shot Increases Protection<blockquote>强生公司表示，第一针注射两个月后的Covid-19疫苗加强剂可增强保护作用</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Says Covid-19 Vaccine Booster Two Months After First Shot Increases Protection<blockquote>强生公司表示，第一针注射两个月后的Covid-19疫苗加强剂可增强保护作用</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-09-21 19:16</span>\n</p>\n</h4>\n</header>\n<article>\n<p> <b>Trial participants in the U.S. who received a second dose eight weeks after the first had 94% protection against the illness.</b> Johnson & JohnsonJNJ-0.57%said a booster dose of its Covid-19 vaccine administered two months after the first shot increased protection against symptomatic illness in trial participants, as federal regulators evaluate data for the country’s strategy for rolling out boosters.</p><p><blockquote><b>美国的试验参与者在第一剂疫苗八周后接受第二剂疫苗，对该疾病的保护率为94%。</b>强生公司(Johnson&JohnsonJNJ-0.57%)表示，在联邦监管机构评估该国推出加强疫苗战略的数据时，在第一针注射两个月后注射了加强剂量的Covid-19疫苗，增强了对试验参与者症状性疾病的保护。</blockquote></p><p> Data released Tuesday from a late-stage clinical trial showed that study participants in 10 countries including the U.S. who received a second dose of the company’s vaccine two months after the first had 75% protection against symptomatic Covid-19. Participants in the U.S. had 94% protection against the illness. J&J didn’t explain the reason for the difference in efficacy rates.</p><p><blockquote>周二发布的一项后期临床试验数据显示，包括美国在内的10个国家的研究参与者在第一剂疫苗两个月后接种了第二剂该公司的疫苗，对有症状的Covid-19有75%的保护作用。美国的参与者对这种疾病有94%的保护。强生没有解释有效率差异的原因。</blockquote></p><p> A double dose of the vaccine provided participants with 100% protection against severe or critical Covid-19 at least two weeks after the second shot, J&J said.</p><p><blockquote>强生表示，在第二次注射后至少两周内，双倍剂量的疫苗为参与者提供了100%的针对严重或危重Covid-19的保护。</blockquote></p><p> The company earlier this year said a large clinical trial showed thata single dose of its vaccine was 66% effectiveat protecting people from moderate to severe Covid-19.</p><p><blockquote>该公司今年早些时候表示，一项大型临床试验表明，其单剂疫苗在保护人们免受中度至重度Covid-19感染方面的有效性为66%。</blockquote></p><p> “We now have generated evidence that a booster shot further increases protection against Covid-19 and is expected to extend the duration of protection significantly,” said Paul Stoffels, chief scientific officer at J&J. The company said it has shared available data with the Food and Drug Administration.</p><p><blockquote>强生首席科学官保罗·斯托菲尔斯(Paul Stoffels)表示：“我们现在有证据表明，加强注射进一步增强了对Covid-19的保护，预计将显着延长保护持续时间。”该公司表示，已与食品和药物管理局分享了可用数据。</blockquote></p><p> The late-stage study tested a two-dose regimen of the vaccine in about 32,000 people aged 18 and over in the U.S., Belgium, Brazil, Colombia, France, Germany, the Philippines, South Africa, Spain and the U.K., J&J said. The company said about half of participants received the placebo but didn’t say how many participants were in the U.S.</p><p><blockquote>J&J说，这项后期研究在美国、比利时、巴西、哥伦比亚、法国、德国、菲律宾、南非、西班牙和英国的约32,000名18岁及以上的人中测试了两剂疫苗。该公司表示，大约一半的参与者接受了安慰剂，但没有透露有多少参与者在美国。</blockquote></p><p> J&J said Tuesday that an extra shot given two months after the firstboosted antibody levels four to six times higherthan observed after the single shot. It said a booster administered six months after the first shot initially increased antibody levels ninefold and continued to climb to 12-fold higher four weeks after the second shot. J&J released some of thesix-month boosting datain August.</p><p><blockquote>强生周二表示，第一次加强抗体水平两个月后额外注射的抗体水平比单次注射后观察到的高出四到六倍。报告称，第一次注射后六个月注射的加强剂最初使抗体水平增加了九倍，并在第二次注射后四周继续攀升至12倍。J&J在8月份发布了一些六个月的提振数据。</blockquote></p><p> Neither that data nor the results released Tuesday have been peer reviewed or published in a scientific journal.</p><p><blockquote>这些数据和周二发布的结果都没有经过同行评审或发表在科学期刊上。</blockquote></p><p> “The data are supportive of giving a second shot of the J&J vaccine, anywhere from two months onwards,” said Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop J&J’s vaccine. “The longer you wait, the better the boost will likely be.”</p><p><blockquote>帮助开发强生疫苗的波士顿贝斯以色列女执事医疗中心免疫学家丹·巴鲁奇(Dan Barouch)表示：“数据支持在两个月后注射第二针强生疫苗。”“等待的时间越长，提振效果可能就越好。”</blockquote></p><p> He said some countries might choose to offer boosters, while others might stick with a single shot. “Different people or different countries might actually make different choices based on what their desires or needs are,” Dr. Barouch said.</p><p><blockquote>他说，一些国家可能会选择提供加强剂，而另一些国家可能会坚持注射一针。“不同的人或不同的国家实际上可能会根据他们的愿望或需求做出不同的选择，”巴鲁奇博士说。</blockquote></p><p> J&J also highlighted data it said showed its single-shot vaccine offered durable protectioneven as the Delta variant spreads.</p><p><blockquote>强生公司还强调了数据，称其单针疫苗即使在德尔塔变异毒株病毒传播的情况下也能提供持久的保护。</blockquote></p><p> In a study of about 390,000 people in the U.S. who received the J&J vaccine compared with 1.52 million similar unvaccinated people from March to late July 2021,the single-dose vaccine was 79% effectiveagainst infections and 81% effective against hospitalizations related to Covid-19.</p><p><blockquote>在一项对2021年3月至7月下旬美国约390,000名接种强生疫苗的人与152万名类似未接种疫苗的人进行的研究中，单剂疫苗对感染的有效率为79%，对与Covid-19相关的住院有效率为81%。</blockquote></p><p> The Biden administration is hoping to begin at least part of its boosting strategy this week. It is waiting for the FDA to authorize additional doses of the vaccine fromPfizerInc.andBioNTech SEfor people who are 65 years old and over or at high risk of developing severe Covid-19. A Centers for Disease Control and Prevention advisory panel is set to discuss the Pfizer boosting strategy on Wednesday and Thursday.</p><p><blockquote>拜登政府希望本周至少开始部分提振战略。它正在等待FDA批准辉瑞公司和BioNTech为65岁及以上或患有严重Covid-19高风险的人群提供额外剂量的疫苗。疾病控制和预防中心顾问小组将于周三和周四讨论辉瑞的加强策略。</blockquote></p><p> Plans to offer boosters more widely were scaled back as federal health officials and medical expertsremain divided over the need for boostersand regulators have asked for more time to review data from J&J andModernaInc.</p><p><blockquote>由于联邦卫生官员和医学专家在加强剂的需求上仍存在分歧，监管机构要求更多时间来审查强生和现代公司的数据，更广泛地提供加强剂的计划被缩减。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/j-j-says-covid-19-vaccine-booster-two-months-after-first-shot-increases-protection-11632220201?mod=hp_lead_pos3\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.wsj.com/articles/j-j-says-covid-19-vaccine-booster-two-months-after-first-shot-increases-protection-11632220201?mod=hp_lead_pos3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157787805","content_text":"Trial participants in the U.S. who received a second dose eight weeks after the first had 94% protection against the illness.\n\nJohnson & JohnsonJNJ-0.57%said a booster dose of its Covid-19 vaccine administered two months after the first shot increased protection against symptomatic illness in trial participants, as federal regulators evaluate data for the country’s strategy for rolling out boosters.\nData released Tuesday from a late-stage clinical trial showed that study participants in 10 countries including the U.S. who received a second dose of the company’s vaccine two months after the first had 75% protection against symptomatic Covid-19. Participants in the U.S. had 94% protection against the illness. J&J didn’t explain the reason for the difference in efficacy rates.\nA double dose of the vaccine provided participants with 100% protection against severe or critical Covid-19 at least two weeks after the second shot, J&J said.\nThe company earlier this year said a large clinical trial showed thata single dose of its vaccine was 66% effectiveat protecting people from moderate to severe Covid-19.\n“We now have generated evidence that a booster shot further increases protection against Covid-19 and is expected to extend the duration of protection significantly,” said Paul Stoffels, chief scientific officer at J&J. The company said it has shared available data with the Food and Drug Administration.\nThe late-stage study tested a two-dose regimen of the vaccine in about 32,000 people aged 18 and over in the U.S., Belgium, Brazil, Colombia, France, Germany, the Philippines, South Africa, Spain and the U.K., J&J said. The company said about half of participants received the placebo but didn’t say how many participants were in the U.S.\nJ&J said Tuesday that an extra shot given two months after the firstboosted antibody levels four to six times higherthan observed after the single shot. It said a booster administered six months after the first shot initially increased antibody levels ninefold and continued to climb to 12-fold higher four weeks after the second shot. J&J released some of thesix-month boosting datain August.\nNeither that data nor the results released Tuesday have been peer reviewed or published in a scientific journal.\n“The data are supportive of giving a second shot of the J&J vaccine, anywhere from two months onwards,” said Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop J&J’s vaccine. “The longer you wait, the better the boost will likely be.”\nHe said some countries might choose to offer boosters, while others might stick with a single shot. “Different people or different countries might actually make different choices based on what their desires or needs are,” Dr. Barouch said.\nJ&J also highlighted data it said showed its single-shot vaccine offered durable protectioneven as the Delta variant spreads.\nIn a study of about 390,000 people in the U.S. who received the J&J vaccine compared with 1.52 million similar unvaccinated people from March to late July 2021,the single-dose vaccine was 79% effectiveagainst infections and 81% effective against hospitalizations related to Covid-19.\nThe Biden administration is hoping to begin at least part of its boosting strategy this week. It is waiting for the FDA to authorize additional doses of the vaccine fromPfizerInc.andBioNTech SEfor people who are 65 years old and over or at high risk of developing severe Covid-19. A Centers for Disease Control and Prevention advisory panel is set to discuss the Pfizer boosting strategy on Wednesday and Thursday.\nPlans to offer boosters more widely were scaled back as federal health officials and medical expertsremain divided over the need for boostersand regulators have asked for more time to review data from J&J andModernaInc.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":1369,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":19,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/869008484"}
精彩评论